A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: The relationship between industry sponsorship and randomized study design

Neela D. Goswami, Ephraim L. Tsalik, Susanna Naggie, William C. Miller, John R. Horton, Christopher Pfeiffer, Charles B. Hicks

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials.gov registry, which allows investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort, the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials.gov registry into a searchable dataset to facilitate research on clinical trials themselves.Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with ClinicalTrials.gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition.Results: The crude PR was 1.17 (95% CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95% CI 0.82, 1.56). There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In stratified tabular analysis the adjusted PR was 1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95% CI 0.50, 2.22) among phase 4 trials.Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further light on the relationship between industry sponsorship and appropriate trial methodology.

Original languageEnglish (US)
Article number31
JournalTrials
Volume15
Issue number1
DOIs
StatePublished - Jan 22 2014

Fingerprint

Hepatitis C
Industry
Cross-Sectional Studies
Clinical Trials
HIV
Random Allocation
Registries
Clinical Trials Data Monitoring Committees
Research
Financial Management
Public Policy
Marketing
Pharmaceutical Preparations
Communicable Diseases
Publications
Acquired Immunodeficiency Syndrome
Regression Analysis
Research Personnel
Prospective Studies
Population

Keywords

  • Bias
  • Industry
  • Methodology
  • Pharmaceutical
  • Randomization
  • Trial

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010 : The relationship between industry sponsorship and randomized study design. / Goswami, Neela D.; Tsalik, Ephraim L.; Naggie, Susanna; Miller, William C.; Horton, John R.; Pfeiffer, Christopher; Hicks, Charles B.

In: Trials, Vol. 15, No. 1, 31, 22.01.2014.

Research output: Contribution to journalArticle

Goswami, Neela D. ; Tsalik, Ephraim L. ; Naggie, Susanna ; Miller, William C. ; Horton, John R. ; Pfeiffer, Christopher ; Hicks, Charles B. / A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010 : The relationship between industry sponsorship and randomized study design. In: Trials. 2014 ; Vol. 15, No. 1.
@article{3c471f5c9a34487395a5e61c2c90904d,
title = "A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: The relationship between industry sponsorship and randomized study design",
abstract = "Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials.gov registry, which allows investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort, the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials.gov registry into a searchable dataset to facilitate research on clinical trials themselves.Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with ClinicalTrials.gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition.Results: The crude PR was 1.17 (95{\%} CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95{\%} CI 0.82, 1.56). There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In stratified tabular analysis the adjusted PR was 1.14 (95{\%} CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95{\%} CI 0.50, 2.22) among phase 4 trials.Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further light on the relationship between industry sponsorship and appropriate trial methodology.",
keywords = "Bias, Industry, Methodology, Pharmaceutical, Randomization, Trial",
author = "Goswami, {Neela D.} and Tsalik, {Ephraim L.} and Susanna Naggie and Miller, {William C.} and Horton, {John R.} and Christopher Pfeiffer and Hicks, {Charles B.}",
year = "2014",
month = "1",
day = "22",
doi = "10.1186/1745-6215-15-31",
language = "English (US)",
volume = "15",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010

T2 - The relationship between industry sponsorship and randomized study design

AU - Goswami, Neela D.

AU - Tsalik, Ephraim L.

AU - Naggie, Susanna

AU - Miller, William C.

AU - Horton, John R.

AU - Pfeiffer, Christopher

AU - Hicks, Charles B.

PY - 2014/1/22

Y1 - 2014/1/22

N2 - Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials.gov registry, which allows investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort, the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials.gov registry into a searchable dataset to facilitate research on clinical trials themselves.Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with ClinicalTrials.gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition.Results: The crude PR was 1.17 (95% CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95% CI 0.82, 1.56). There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In stratified tabular analysis the adjusted PR was 1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95% CI 0.50, 2.22) among phase 4 trials.Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further light on the relationship between industry sponsorship and appropriate trial methodology.

AB - Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials.gov registry, which allows investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort, the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials.gov registry into a searchable dataset to facilitate research on clinical trials themselves.Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with ClinicalTrials.gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition.Results: The crude PR was 1.17 (95% CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95% CI 0.82, 1.56). There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In stratified tabular analysis the adjusted PR was 1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95% CI 0.50, 2.22) among phase 4 trials.Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further light on the relationship between industry sponsorship and appropriate trial methodology.

KW - Bias

KW - Industry

KW - Methodology

KW - Pharmaceutical

KW - Randomization

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=84892654848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892654848&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-15-31

DO - 10.1186/1745-6215-15-31

M3 - Article

C2 - 24450313

AN - SCOPUS:84892654848

VL - 15

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 31

ER -